Please enable Javascript
Shahla Bari, MD
Shahla Bari, MD, of Duke Cancer Institute
Articles by Shahla Bari, MD
Future Directions in nccRCC: SAMETA, FORTUNE, and Second-Line Treatment
Laurence Albiges, MD, PhD
nccRCC
|
July 29, 2024
The panel concludes with an overview of advancements and upcoming trials in the treatment of nccRCC.
View More
Adjuvant Setting, Toxicity Considerations for Single-Agent, Combination nccRCC Therapy
Laurence Albiges, MD, PhD
nccRCC
|
July 29, 2024
The panel weighs the progress and challenges of adjuvant pembro and addresses the toxicity profiles of IO/TKI regimens.
View More
Management Round-Up: Translocation, Chromophobe, RMC, and Other Subtypes
Laurence Albiges, MD, PhD
nccRCC
|
July 29, 2024
The panel delves into the challenges and treatment approaches for various rare subtypes of nccRCC, including translocation.
View More
Evolution of Combination Therapy in nccRCC, Papillary Subtype
Laurence Albiges, MD, PhD
nccRCC
|
July 26, 2024
The panel highlights recent advancements in combination therapies for nccRCC, with a focus on KEYNOTE-B61 and cabo-nivo.
View More
Managing Metastatic nccRCC: Historical Approaches and Current Changes
Laurence Albiges, MD, PhD
nccRCC
|
July 23, 2024
The panel focuses on CN, oligometastatic disease treatment, and advancements in systemic therapies over the past few decades.
View More
Defining and Prognosticating nccRCC: Constant Molecular Evolution
Laurence Albiges, MD, PhD
nccRCC
|
July 23, 2024
The panel explores our understanding of nccRCC, including classification, molecular distinctions, and prognostic criteria.
View More